Skip to main content

LCD L34771: Immune Globulins

LCD L34771, Immune Globulins, is the Local Coverage Determination that Wisconsin Physicians Service Insurance Corporation applies to claims from 48 states (AK, AL, AR, AZ, CA, CO, CT, DE and others), effective 2026-02-26 and first in force 2015-10-01. The policy text runs 1,533 words, and its billing and coding article A57554 lists 1,176 ICD-10-CM codes that support medical necessity for 28 procedure codes. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wisconsin Physicians Service Insurance Corporation
States and territories
48
AK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY
Revision effective
2026-02-26
Original effective
2015-10-01
Policy text
1,533 words
Covered ICD-10 codes (articles)
1176

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L34771
ContractContractorTypeStates
05101Wisconsin Physicians Service Insurance CorporationMAC - Part AIA
05201Wisconsin Physicians Service Insurance CorporationMAC - Part AKS
05301Wisconsin Physicians Service Insurance CorporationMAC - Part AMO
05401Wisconsin Physicians Service Insurance CorporationMAC - Part ANE
05102Wisconsin Physicians Service Insurance CorporationMAC - Part BIA
05202Wisconsin Physicians Service Insurance CorporationMAC - Part BKS
05302Wisconsin Physicians Service Insurance CorporationMAC - Part BMO
05402Wisconsin Physicians Service Insurance CorporationMAC - Part BNE
08101Wisconsin Physicians Service Insurance CorporationMAC - Part AIN
08102Wisconsin Physicians Service Insurance CorporationMAC - Part BIN
08201Wisconsin Physicians Service Insurance CorporationMAC - Part AMI
08202Wisconsin Physicians Service Insurance CorporationMAC - Part BMI
05901Wisconsin Physicians Service Insurance CorporationMAC - Part AAK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY

Billing and coding article A57554: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A57554 (Billing and Coding: Immune Globulins) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A57554: Billing and Coding: Immune Globulins (Billing and Coding, effective 2026-07-01)

Covered ICD-10-CM codes
1176
14 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
28
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A57554
ICD-10-CMDescription (FY2027)
B16.1Acute hepatitis B with delta-agent without hepatic coma
B16.2Acute hepatitis B without delta-agent with hepatic coma
B16.9Acute hepatitis B without delta-agent and without hepatic coma
B17.0Acute delta-(super) infection of hepatitis B carrier
B18.0Chronic viral hepatitis B with delta-agent
B18.1Chronic viral hepatitis B without delta-agent
B19.10Unspecified viral hepatitis B without hepatic coma
B19.11Unspecified viral hepatitis B with hepatic coma
B20Human immunodeficiency virus [HIV] disease
C88.20Heavy chain disease not having achieved remission
C88.21Heavy chain disease, in remission
C88.30Immunoproliferative small intestinal disease not having achieved remission
C88.31Immunoproliferative small intestinal disease, in remission
C88.80Other malignant immunoproliferative diseases not having achieved remission
C88.81Other malignant immunoproliferative diseases, in remission
C88.90Malignant immunoproliferative disease, unspecified not having achieved remission
C88.91Malignant immunoproliferative disease, unspecified, in remission
C90.00Multiple myeloma not having achieved remission
C90.01Multiple myeloma in remission
C90.02Multiple myeloma in relapse
C90.10Plasma cell leukemia not having achieved remission
C90.11Plasma cell leukemia in remission
C90.12Plasma cell leukemia in relapse
C90.20Extramedullary plasmacytoma not having achieved remission

Procedure codes: 90371, 90375, 90376, 90393, 90396, 96365, 96366, 96372, J0840 (Injection, crotalidae polyvalent immune fab (ovine), up to 1 gram), J0850 (Injection, cytomegalovirus immune globulin intravenous (human), per vial), J1459 (Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1460 (Injection, gamma globulin, intramuscular, 1 cc), J1552 (Injection, immune globulin (alyglo), 500 mg), J1554 (Injection, immune globulin (asceniv), 500 mg), J1556 (Injection, immune globulin (bivigam), 500 mg), J1557 (Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1560 (Injection, gamma globulin, intramuscular, over 10 cc), J1561 (Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg), J1566 (Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg), J1568 (Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1569 (Injection, immune globulin, (gammagard liquid/gammagard liquid erc), 500 mg), J1571 (Injection, hepatitis b immune globulin (hepagam b), intramuscular, 0.5 ml), J1572 (Injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g., liquid), 500 mg), J1573 (Injection, hepatitis b immune globulin (hepagam b), intravenous, 0.5 ml), J1575 (Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin), J1577 (Injection, immune globulin (qivigy), 100 mg), J1599 (Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg), J1670 (Injection, tetanus immune globulin, human, up to 250 units).

Coverage indications, limitations and medical necessity

Immune serums (immune globulin) provide passive immunity to infectious disease. The protection will be of rapid onset, but of short duration (1-3 months). Immune sera are obtained from pooled human plasma of either general population donors or hyperimmunized donors. It may be administered either by intravenous (IV) or intramuscular (IM) injection.

• Immune globulin is available in broad-spectrum form, or disease-specific hyperimmune serum.

• Gamma Globulin; intramuscular IG, Gamma Globulin, ISG, Gamastan, Gammar, is indicated for the following conditions:

• Hepatitis A exposure.

• Measles (Rubeola): for a susceptible patient (has not been vaccinated or had measles and is at high risk for complication) who has been exposed less than 3 days prior to treatment.

• Rubella: for a woman in early pregnancy, who is exposed to the virus and does not have immunity.

• Varicella: for passive immunization in immunosuppressed patients when varicella zoster immunoglobulin is not available.

• Immunoglobulin deficiency: for prevention of serious infection when circulating IgG levels are low. Prophylactic therapy, especially against infections due to encapsulated bacteria, is often effective in Bruton-type, sex-linked congenital agammaglobulinemia, agammaglobulinemia associated with thymoma, and acquired agammaglobulinemia.

• Specific hyperimmune serum globulin includes several different disease-specific drugs.

• Hepatitis B serum is indicated post-exposure for transient prevention of hepatitis B infection.

• Rabies serum is indicated post-exposure for transient prevention of rabies infection when the patient has not been completely immunized with the vaccination.

• Vaccinia serum is indicated for transient prevention of, or modification of aberrant infections induced by vaccinia (smallpox) vaccine, the vaccinia virus, such as eczema vaccinatum, some cases of progressive vaccinia, and possibly ocular vaccinia.

• Varicella-zoster serum is indicated for transient prevention of varicella-zoster infection in exposed, susceptible individuals who have a greater risk of complications from varicella. Documentation in the progress notes must indicate one of the following complicating conditions to verify medical necessity:

- Personal history of leukemia or lymphoma

- HIV infection

- Current immunosuppressive therapy

- A newborn with exposure to chickenpox (the documentation must indicate why the newborn is at increased risk; e.g., if the mother was exposed within 5 days of delivery).

• Tetanus serum is indicated for transient protection against tetanus post-exposure to tetanus. Documentation in the progress notes must identify the following:

- The wound is other than a clean minor wound, and the date of the injury;

- The active immunization with tetanus toxoid is unknown or uncertain; or

- The patient has received either less than 2 prior doses of tetanus toxoid; or 2 prior doses of tetanus toxoid, but there has been a delay of 24 hours or more between the time of injury and the initiation of tetanus prophylaxis.

• Cytomegalovirus (CMV) immune globulin intravenous (CMV-IGIV) (human) per vial is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, heart, stem cell, and pancreas. In transplants of these organs other than kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IGIV should be considered in combination with ganciclovir.

• Hepatitis B immune globulin (HepaGam B) intramuscular , 0.5 ml is indicated for the treatment of acute exposure to blood containing Hepatitis B Surface Antigen (HBsAg), perinatal exposure of infants born to HBsAg positive mothers, sexual exposure to HBsAg-positive persons, and household exposure to persons with acute HBV infection.

• HepaGam B intravenously is indicated for the prevention of Hepatitis B recurrence following a liver transplantation, in HBsAg-positive liver transplant patients.

• Crotalidae polyvalent immune FAB (OVINE), (CroFab)

CroFab is indicated for the management of patients with minimal or moderate envenomation from North American rattlesnakes, copperheads, and cottonmouths/water moccasins. Early use of CroFab (within 6 hours of snakebite) is advised to prevent clinical deterioration and the occurrence of systemic coagulation abnormalities.

• Intravenous immune globulin (Sandoglobulin, Venoglobulin-I, Privigen, Gamunex, Octagam, Gammagard liquid, Flebogamma/Flebogamma DIF, Carimune, Gammaplex, Bivigam) provides immediate antibody levels. IVIG may be indicated for the following conditions:

• Immunodeficiency Syndrome: to include congenital agammaglobulinemia such as x-linked agammaglobulinemia, common variable hypoglobulinemia, x-linked immunodeficiency with hyper IGM, combined immunodeficiency.

• Primary thrombocytopenia.

• Alloimmune thrombocytopenia, refractoriness to platelet transfusions. Routine use is not indicated. IVIG may have a role in patients with severe thrombocytopenia of documented immune basis for whom other modalities are unsuccessful or contraindicated.

• Post-transfusion purpura. IVIG may be considered as first-line therapy in severely affected patients.

• Lymphoid Leukemia with either hypogammaglobulinemia or recurrent bacterial infections.

• Autoimmune hemolytic anemia (AIHA). Routine use is not indicated. IVIG may have a role in patients with warm-type AIHA that does not respond to corticosteroids.

• Immune-mediated neutropenia. Routine use is not indicated. IVIG may have a role in severe illness that does not respond to other modalities or when the latter are contraindicated.

• Multiple Myeloma. Routine use is not indicated. It may have a role in patients with stable (plateau phase) disease and high risk of recurrent infections.

• Pediatric intractable epilepsy. Routine use is not indicated. IVIG may have a role in certain syndromes as a last resort, especially in patients who may be candidates for surgical resection.

• Guillain-Barré syndrome. IVIG is recommended as an equivalent alternative to plasma exchange in children and adults.

• Myasthenia gravis (MG). Routine use is not indicated. IVIG may be considered in patients with severe MG to treat acute severe decompensation when other treatments have been unsuccessful or are contraindicated.

• Eaton-Lambert Syndrome. This is an immune-mediated, myasthenia-like syndrome. Treatment with IVIG is directed at decreasing the autoimmune response.

• Polyneuropathy, chronic inflammatory demyelinating. IVIG is recommended as an equivalent alternative to plasma exchange in adults.

• Multifocal motor neuropathy. The routine use of IVIG is not usually recommended. IVIG may be considered in patients who have progressive, symptomatic multifocal motor neuropathy that has been diagnosed on the basis of electrophysiologic findings that rule out other possible conditions that may not respond to this treatment.

• Dermatomyositis. Routine use is not indicated. IVIG may be used for patients with severe active illness for whom other interventions have been unsuccessful or intolerable.

• Polymyositis. Routine use is not indicated. IVIG may be used for patients with severe active illness for whom other interventions have been unsuccessful or intolerable.

• Systemic lupus erythematosus (SLE). Routine use is not indicated. IVIG may be used for patients with severe active SLE for whom other interventions have been unsuccessful or intolerable.

• Systemic sclerosis dermatomyositis overlap syndrome. Routine use is not indicated. IVIG may be used for patients with severe active illness for whom other interventions have been unsuccessful or intolerable.

• Kawasaki disease.

• Severe Vasculitic Syndromes, systemic (polyarteritis nodosa), Churg-Strauss Vasculitis, and livedoid vasculitis (atrophie blanche). Evidence does not support routine use of IVIG. IVIG may be used for patients with severe active illness for whom other interventions have been unsuccessful or intolerable.

• Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome. Evidence does not support routine use of IVIG. It will be covered if it is refractory to conventional therapy.

• Pemphigoid gestationis that is refractory to conventional therapy.

• Pyoderma gangrenosum that is refractory to conventional therapy.

• Neonatal alloimmune thrombocytopenia. Routine use of IVIG is not recommended. It is recommended in severely thrombocytopenic, symptomatic neonates who are at high risk of developing intracranial hemorrhage when other interventions have been unsuccessful, become intolerable, or are contra-indicated.

• IVIG may be indicated for high-risk pregnant women who have had a history of a previously affected infant with fetal-neonatal thrombocytopenia.

• Wiskott-Aldrich Syndrome.

• Anemia due to pure red cell aplasia.

• Human Immunodeficiency Virus (HIV) infection. IVIG will be covered for patients infected with HIV to reduce significant bacterial infection when all the following coverage indicators are present: a) age less than 13 years old; b) evidence of either qualitative or quantitative humoral immunologic defects and c) current bacterial infections, despite appropriate antimicrobial prophylaxis. Dosage Guidelines: 400 mg/kg body weight given every 28 days.

• Autoimmune mucocutaneous blistering disease is covered by a National Coverage Determination (See Pub 100-3: Medicare National Coverage Determination Manual Chapter 1, Part 4 Section 250.3).

• Stiff-man syndrome. IVIG may be used for patients with severe active illness for whom other interventions have been unsuccessful or intolerable.

• Desensitization for a pre-kidney transplantation in patients with a panel reactive antibody (PRA) of 80% or below. Use in patients with a PRA of 81-100% is considered to be experimental/ investigation and is therefore not covered. Post transplantation to prevent rejection remains covered without regard to antibody levels.

• Scleromyxedema, mucinosis of the skin, focal mucinosis, lichen myxedematosus, or reticular erythematous mucinosis.

• Subcutaneous immune globulin (Hyqvia)

• Hyqvia is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of Primary Immunodeficiency (PI) in adults. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. Hyqvia is administered subQ on an infusion pump which has the ability to titrate the flow rate up or down if required to improve tolerability. WPS GHA Part B will cover the cost as “incident to” for a maximum of 2 episodes to provide teaching in the office setting, effective 12/15/2016. For subsequent doses and titration, coverage shifts to the DME MAC.

Summary of evidence (opening)

N/A

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2026-02-26
Last reviewed by the contractor
2026-01-15
MCD version
51
Derived from
L30147

The contractor lists one National Coverage Determination as related: NCD 250.3 Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wisconsin Physicians Service Insurance Corporation hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L34771 cover?

Immune serums (immune globulin) provide passive immunity to infectious disease. The protection will be of rapid onset, but of short duration (1-3 months). Immune sera are obtained from pooled human plasma of either general population donors or hyperimmunized donors. It may be administered either by intravenous (IV) or intramuscular (IM) injection. The full 1,533-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L34771 apply to?

Wisconsin Physicians Service Insurance Corporation applies it to Medicare claims in 48 states: AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L34771?

The companion billing and coding article A57554 lists 1,176 ICD-10-CM codes in 14 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L34771?

A denial under LCD L34771 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A57554's 1,176 covered diagnosis codes, then file a redetermination with Wisconsin Physicians Service Insurance Corporation within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.